Thermo Fisher Scientific on Wednesday announced the expansion of its clinical research operations with the opening of a bioanalytical lab in Richmond, VA.
The new unit will support increasing demand from biopharma firms for consistent, high-quality laboratory services to accelerate drug development, the firm said.
The 59,000-square-foot facility is part of the previously announced $97 million investment to expand its bioanalytical laboratory operations in Richmond and add more than 500 jobs over the next three years, according to Thermo Fisher.
The company acquired the current laboratory services operation in Richmond with the purchase of PPD in December 2021.
The bulk of the expansion will facilitate liquid chromatography-mass spectrometry for drug discovery and clinical testing, as well as subsequent enhancements in cell and gene therapy, biomarkers, vaccine sciences, and immunochemistry, Thermo Fisher said.